Replies to post #18054 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

....does phase one results justify this kind of price action?

A resounding - YES

From corporate presentation (slides) - August 2017 - Pg. 14

M281 along with M230 & 254 are Targeting -
OVER 70 distinct disease indications

I.E. Prevalent AI Diseases
RA, Psoriasis, Psoriatic arthritis, Crohn’s, Ulcerative colitis, Ankylosing spondyliti

http://ir.momentapharma.com/static-files/9199d6b1-af62-4c48-bf78-c62cd895143d

also, see poster (dated 2015) -

http://www.momentapharma.com/docs/EULAR-poster-68inX35in-FINAL.pdf

In addition, you have to remember yesterday's announcement - M710

Thank you, Dr. Tony Manning & staff.